{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"}]}],"title":"No. of patients with grade 0, no mucositis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]}],"title":"No. of patients with grade 1, mild mucositis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}],"title":"No of patients with grade 2, moderate mucositis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"No of patients with grade 3, severe mucositis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"No. of patients with grade 4, disabling mucositis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"No. of patients with grade 5 mucositis, death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"description":"Measured by Common Toxicity Criteria (CTC) v. 3.00 = no mucositis (minimum score), 1 = mild mucositis, 2 = moderate mucositis, 3 = severe mucositis, 4 = life-threatening, disabling mucositis, 5 = death (worst score).","groups":[{"description":"Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.","id":"OG000","title":"Arm IA"},{"description":"Patients undergo SNT and low weight resistance training (LWRT).","id":"OG001","title":"Arm IB"},{"description":"Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.","id":"OG002","title":"Arm IIA"},{"description":"Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.","id":"OG003","title":"Arm IIB"}],"paramType":"NUMBER","populationDescription":"Participants available for 6-month follow-up oral examination. No 6-month follow-up data were available for the following numbers of patients: Arm 1A (1), Arm 1B (4), Arm 2A (3), Arm 2B (2).","reportingStatus":"POSTED","timeFrame":"6 months after concurrent chemotherapy and radiation","title":"Number of Patients With Oral Mucositis by Grade","type":"SECONDARY","unitOfMeasure":"participants"}